François Ferré, Ph.D. | Co-Founder & Chairman
François is the co-CEO of ALMA Life Sciences LLC, an investment and consulting firm. Additionally, he was the CEO of AltheaDx from 2010 to June 2013 and prior to, he co-founded Althea Technologies and served as co-CEO from 1998 until 2008. After Althea Technologies was successfully acquired by Ajinomoto in 2013, he served as a Director at Ajinomoto-Althea until 2019. He currently serves on numerous boards such as Agendia and Neuralace. He is a Managing Director of Mesa Verde Venture Partners and he is a Board member of La Jolla Institute of Allergy and Immunology. Francois has been at the forefront of genomics and molecular diagnostics for three decades and has published several authoritative reviews on these topics, including the co-edition of a bestseller book on PCR with Nobel Prize winner, Dr. Kary Mullis. He received his PhD in molecular oncology from the Pasteur Institute, France and did his post-doctoral training at the University of California, San Diego.
Dan Bradbury | Director
Dan has over 35 years of experience creating and implementing strategies that transform businesses and bring novel medicines to market. He is the Managing Member of BioBrit, LLC, a Life Sciences Consulting and Investment Firm based in La Jolla, CA. Dan also is the Executive Chairman and Co-Founder of Equillium, Inc. (NASDAQ: EQ), a publicly traded biopharmaceutical company where he served as CEO until January 2020. He is the former President, CEO and Director of Amylin Pharmaceuticals where during his 18-year tenure, the company launched three first-in-class medicines, including the first once-a-week therapy to treat diabetes. He led the company’s acquisition by Bristol-Myers Squibb Company in August 2012. Prior to Amylin, Dan worked in marketing and sales roles for ten years at SmithKline Beecham Pharmaceuticals. Dan serves on numerous public company board of directors, including: Biocon Limited, Castle Biosciences, Inc., Equillium, Inc., Intercept Pharmaceuticals, Inc., and Panacea Acquisition Corporation. Dan received a Bachelor of Pharmacy from Nottingham University and a Diploma in Management Studies from Harrow and Ealing Colleges of Higher Education in the United Kingdom.
Derek joined the BOD in May 2021, and is the Founder and CEO of NASDAQ-listed Castle Biosciences since 2007. Previously he held leadership roles at Encysive Pharmaceuticals, Amylin Pharmaceuticals, Sandoz and Schering-Plough. Derek brings a wealth of commercialization and marketing experience, having served in Director and VP roles in: Marketing, Sales & Marketing, and Business Development. Castle Biosciences has gained successful Medicare reimbursement coverage and has overseen successful launches of their three diagnostic tests in melanoma and one in cutaneous squamous cell carcinoma.
David Nikodem, Ph.D. | CEO and Director
David joined AltheaDx in December 2018 as Interim CEO and then continued to permanent CEO in January 2020, leading the team to a successful reimbursement decision at CMS. He has served on the Board of Directors of AltheaDx since December 2015 as a representative of Ally Bridge Group, where he led a private investment for a syndicate of investors in 2015. Prior to AltheaDx, David was a healthcare industry investor, both in public equites, as well as venture capital, where he served on numerous Boards of Directors. He obtained his Ph.D. from Georgetown University and an undergraduate degree from The University of Virginia.